TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M

TELA Bio, Inc.

2022-Q3 EPS reported -$2.24 revenue$29,796,000

Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.
Net loss $10.7M vs $8.3M; operating loss $9.5M vs $7.2M in Q3 2021.
Reaffirmed FY2022 revenue guidance $42-45M (43-53% growth over FY2021).
OviTex revenue +29% YoY, OviTex PRS +108% YoY; BRAVO study shows 2.6% recurrence rate.
Closed August oversubscribed public offering netting $34.4M; cash $54.2M at quarter end.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TELA Bio, Inc. reported the third quarter ended September 30, 2022 results: revenue $11.2 million, net income $10.7 million. Guidance reaffirmed.

Period: the third quarter ended September 30, 2022
Revenue: $11.2 million
Net income: $10.7 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights · Reported revenue of $11.2 million for the third quarter, representing growth of 46% over the same quarter of 2021; · Increased demand for OviTex ® and OviTex PRS Reinforced Tissue Matrix products in the third

View on SEC.gov

49 earnings releases filed in the last 30 days. Browse all earnings releases →

TELA Bio, Inc. filing history →

Source: SEC EDGAR

accession 0001104659-22-116468

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.